Sirtris advances new therapies to combat aging

This exciting company reminds me of another New York Times (NYT) Monday morning call of medical breakthrough. If you'll recall, Entremed had done cancer studies on rats that showed the rats responsive to their therapy and the NYT jumped all over it. The Entremed stock leapt over four fold the next day and plenty of money was made, save for the fact that the research was theory, rat models rarely convert into human equivalents and the push in PR from the NYT, is often based on shoddy journalistic principals with the desire to print a leading edge piece without the background. Now that this recent love-company is being promoted as the anti-aging messiah, few would dare to say; "sounds interesting, but call me back in phase II after hundreds of millions has been spent on the resveretrol promise. Being conservative is a requirement, but being skeptical in this field is also necessary, especially with big pharma now trying to suggest that the antioxidant based theory will apply to diabetes. No proof, just conjecture. Good luck gentlemen. I hope you succeed, but for goodness sakes, tone down your enthusiasm so we don't have to wade through all the collateral material and can evaluate the science on it's merits.

LORNE CAPLAN

Is this the same Lorne Caplan that was convicted of wire fraud?